Call Us: 1.800.873.5297

By

FDA Approves Geodon to Help Treat Adult Bipolar Disorder

The Food and Drug Administration has announced it has approved the Pfizer manufactured drug Geodon Capsules (ziprasidone HCl) for the adjunctive treatment of bipolar I disorder in adults. The approval is based on clinical data which demonstrates Geodon is well tolerated in patients as an adjunct to lithium or valproate. The long term treatment of patients with bipolar disorder requires antipsychotics to help manage mood episodes, which can have a devastating effect on patients’ lives, as well as those around them.

The data for Geodon shows that intervention was required in nearly 20 percent of patients who suffered a mood episode and were given the drug for six months compared to over 32 percent who were given a placebo.

Geodon was approved by the FDA in 2001 to treat acute manic and mixed episodes due to bipolar disorder, as well as for treatment of schizophrenia.

Adverse Side Effects

Side effects associated with Geodon are most commonly dizziness, abnormal vision, somnolence, extrapyramidal symptoms, and akathisia. Geodon is not approved for treating the elderly for dementia due to an increased risk of death. Patients who are known to have heart problem or be at a greater risk of heart failure should also not be given this medication.

Neruoleptic malignant syndrome (NMS) has been associated with all antipsychotics including Geodon. This rare condition may cause:

  • Hyperprexia
  • Muscle rigidity
  • Diaphoresis
  • Tachycardia
  • Irregular pulse or blood pressure
  • Cardiac dysrhythmia
  • Altered mental status

Other serious conditions that may occur with taking Geodon include tardive dyskinesia, serious hyperglycemic events, and respiratory tract infections. The risk of rash, orthostatic hypotension, and seizures is also present.

If you or a loved one has been injured by taking Geodon, please contact the experienced drug injury lawyers at Schlichter, Bogard & Denton for an initial case consultation. We serve clients in Kansas City, Missouri, as well as nationwide.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.